Table II.
Development of PET and SPECT Radioligands for the 5-HT System Designed for Use in Human Subjects
| Target | Type | Radioligand | Rodent | Nonhuman primate | Human | Ongoing studies | Reason for failure | Known problems |
|---|---|---|---|---|---|---|---|---|
| 5-HT1A | SPECT | [123I]p-MPPI | ✔ | ✔ | × | – | No specific 5-HT1A binding Rapid metabolism Possible brain exclusion via efflux transporter | – |
| PET | [11C]WAY-100635 | ✔ | ✔ | ✔ | ✔ | – | Fast systemic metabolism; difficult kinetic modelling with arterial input function, reference tissue models complicated by radiometabolites in plasma | |
| [11C]CPC-222 | ✔ | ND | ✔ | ND | Lower signal-to-background ratio than [11C]WAY-100635 | |||
| [11C](R)-RWAY | × | ✔ | × | – | Possible influx of lipophilic radiometabolite | P-gp substrate in rodent | ||
| [11C]DWAY | ✔ | ✔ | ✔ | ND | Unreliable radiolabelling technique; low radioactive yield | |||
| [18F]6FPWAY | ND | ✔ | × | – | Moderate uptake | – | ||
| [18F]MPPF | ✔ | ✔ | ✔ | ✔ | – | P-gp substrate; fast brain clearance and low uptake | ||
| [18F]FCWAY | ✔ | ✔ | ✔ | ✔ | – | Defluorination of parent compound; sub-optimal imaging | ||
| [18F]MefWAY | ND | ✔ | ND | – | ||||
| [11C]NAD-299 | ND | ✔ | ND | – | ||||
| [11C]CUMI-101 | ✔ | ✔ | ✔ | – | Partial, not full agonist | |||
| 5-HT1B | PET | [11C]AZ10419369 | ND | ✔ | ✔ | – | ||
| [11C]P943 | ND | ✔ | ✔ | ✔ | – | |||
| 5-HT2A | SPECT | [123I]DOI | × | × | – | – | Low target-to-background ratio | Non-selective (5-HT2C) |
| [123I]MSP | ✔ | ND | ND | ND | ||||
| [123I]-R91150 | ✔ | ✔ | ✔ | ✔ | – | Lower target-to-background ratio than equivalent PET tracers | ||
| [123I]-3-I-CO | × | ND | – | – | – | Low target-to-background ratio, possible P-gp substrate | ||
| PET | [11C]Ketanserin | ND | ND | × | – | Low target-to-background ratio, fast metabolism | Non-selective (α1, H1, 5-HT2C) | |
| [11C]NMSP | ND | ND | ✔ | – | – | Non-selective (D2) | ||
| [11C]MBL | ND | ✔ | ✔ | – | Non-selective (some D2, α1, 5-HT1 and 5-HT2C) | |||
| [18F]setoperone | ✔ | ✔ | ✔ | ✔ | – | Non-selective (D2) | ||
| [18F]altanserin | ✔ | ✔ | ✔ | ✔ | – | Need for bolus-infusion due to radiometabolites requiring complex modelling using other methods. Possible mixed pharmacology | ||
| [18F]deuteroaltanserin | ND | ✔ | ✔ | ✔ | – | |||
| [18F]RP62203 | ✔ | ND | – | – | Multi-step radiosynthesis | |||
| [11C]MDL100907 | ✔ | ✔ | ✔ | ✔ | – | Arterial input function needed | ||
| [18F]MH.MZ | × | ND | ND | – | Extensive first-pass metabolism, slow washout | - | ||
| (R)-[18F]MH.MZ | ✔ | ND | ND | |||||
| [11C]Cimbi-5 and 36 | ✔ | ✔ (pig) | ND | ND | ||||
| 5-HT3 | PET | [11C]MDL 72222 | × | × | – | – | Lack of specific binding, high lipophilicity | Low 5-HT3 brain density |
| [11C]YM060, [11C]Y-25130 | × | – | – | – | Low brain uptake, low lipophilicity, ionisation of tertiary amide | |||
| [11C]KF17643 | × | – | – | – | No specific binding | |||
| [11C]S21007 | × | × | – | – | No specific binding | |||
| [18F]MR18445 | × | × | – | – | No specific binding | |||
| [11C]NMQ | × | × | – | – | Rapid kinetics, high non-specific binding | |||
| 5-HT4 | SPECT | [123I]SB207710 | × | ✔ | ND | – | – | |
| PET | [11C]SB207145 | ✔ | ✔ (pig) | ✔ | ✔ | – | Slow kinetics | |
| 5-HT6 | PET | [18F]12ST05 | × | – | – | – | No specific binding | – |
| [11C]GSK215083 | ND | ✔ (pig) | ✔ | |||||
| [11C]GSK224558 | ND | (pig only) | ND | – | Inferior ligand compared with [11C]GSK215083 | |||
| 5-HT7 | PET | [11C]DR4446 | ND | × | – | – | Minimal specific binding | – |
| SERT | SPECT | β-[123I]CIT, nor-β-[123I]CIT | ✔ | ✔ | ✔ | ✔ | – | Non-selective (DAT, NET) |
| [123I]ADAM | ✔ | ✔ | ✔ | ✔ | – | Lower resolution than equivalent PET tracers. Ratio method of quantification over-estimates specific binding | ||
| PET | [11C]McN5652 | ✔ | ✔ | ✔ | ✔ | – | Slow brain uptake, irreversible kinetics complicate quantification | |
| [11C]DASB | ✔ | ✔ | ✔ | ✔ | – | |||
| [11C]MADAM | ND | ✔ | ✔ | ✔ | – | |||
| [18F]ADAM | ✔ | ✔ | ND | – | – | |||
| 5-HT synthesis | [11C]-AMT | ✔ | ✔ | ✔ | ✔ | – | Low target-to-background ratio, analysis complicated by possible blood-brain barrier exchange and additional metabolic pathways | |
| [11C]-HTP | ✔ | ✔ | ✔ | ✔ | – | Lack of correlation with [11C]-AMT in direct comparison suggests further validation is necessary |
✔ indicates that ex vivo, PET, or SPECT studies were performed and the ligand was considered successful in the species identified. In certain instances, radioligands were tested in pig brain either in addition to, or instead of nonhuman primate. × indicates that ex vivo, PET, or SPECT studies were performed but the ligand was not considered successful in the species indicated. “Ongoing studies” indicate that the ligand is still being used for research or clinical purposes in humans. ND indicates not yet determined, i.e. experiments have not been published in the species indicated. Missing data are either not applicable (−) or not available/not known (blank cells).